iDoseTR Approval Sets Stage for Glaukos ' Game-Changing Product, Surpassing Market Expectations, Says Analyst

Thursday, the FDA approved Glaukos Corporation's GKOS marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure in patients with ocular hypertension or open-angle…#fda #glaukoscorporation #idosetr #williamblair #idose
Source: Reuters: Health - Category: Consumer Health News Source Type: news